Literature DB >> 25688837

Aberrant activation of atypical protein kinase C in carbon tetrachloride-induced oxidative stress provokes a disturbance of cell polarity and sealing of bile canalicular lumen.

Yosuke Horikoshi1, Kanae Kitatani2, Kentaro Toriumi3, Nahoko Fukunishi4, Yoshiko Itoh4, Naoya Nakamura3, Shigeo Ohno5, Tatsuya Matsura6, Susumu Takekoshi7.   

Abstract

Polarized hepatocytes contain tight junctions (TJs), which are among the most important junctions for sealing the bile canalicular lumen from the sinusoidal space. Alterations in TJs are implicated in chronic cholestatic liver diseases, such as primary biliary cirrhosis and primary sclerosing cholangitis, which have lipid peroxidation marker elevations or antioxidant vitamin decreases. However, the effect of oxidative stress on hepatocyte polarity or liver morphology is unknown. We found that carbon tetrachloride (CCl4)-induced oxidative stress resulted in disassembly of TJs. Ultrastructural analysis revealed disruption in TJs, Golgi morphology, and expansion of the bile canalicular lumen size in CCl4-treated hepatocytes. The Par complex [Par-3-atypical protein kinase C (aPKC) and Par-6 ternary complex] regulates TJs and lumen formation, and the Par-3-aPKC complex formation was inhibited by CCl4 treatment. Moreover, the antioxidant compound vitamin E prohibited a CCl4-induced disturbance in TJs and Par-3-aPKC complex formation. aPKC phosphorylates Par-3 and down-regulates its own affinity with Par-3. Importantly, aPKC kinase activity and Par-3 phosphorylation were significantly increased in CCl4-treated rat livers. These results indicate that the Par-3-aPKC complex plays a crucial role in the maintenance of hepatocyte polarity and sealing of the bile canalicular lumen. Our findings suggest that bile canalicular lumen expansion might explain the presence of cholestasis in patients with primary biliary cirrhosis and primary sclerosing cholangitis.
Copyright © 2015 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25688837     DOI: 10.1016/j.ajpath.2014.12.015

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  5 in total

1.  SEW2871 attenuates ANIT-induced hepatotoxicity by protecting liver barrier function via sphingosine 1-phosphate receptor-1-mediated AMPK signaling pathway.

Authors:  Zhenzhou Jiang; Luyong Zhang; Tingting Yang; Xue Wang; Yi Zhou; Qiongna Yu; Cai Heng; Hao Yang; Zihang Yuan; Yingying Miao; Yuanyuan Chai; Ziteng Wu; Lixin Sun; Xin Huang; Bing Liu
Journal:  Cell Biol Toxicol       Date:  2021-01-05       Impact factor: 6.691

Review 2.  Structural and functional hepatocyte polarity and liver disease.

Authors:  Paul Gissen; Irwin M Arias
Journal:  J Hepatol       Date:  2015-06-24       Impact factor: 25.083

3.  Low-dose acetaminophen induces early disruption of cell-cell tight junctions in human hepatic cells and mouse liver.

Authors:  Wesam Gamal; Philipp Treskes; Kay Samuel; Gareth J Sullivan; Richard Siller; Vlastimil Srsen; Katie Morgan; Anna Bryans; Ada Kozlowska; Andreas Koulovasilopoulos; Ian Underwood; Stewart Smith; Jorge Del-Pozo; Sharon Moss; Alexandra Inés Thompson; Neil C Henderson; Peter C Hayes; John N Plevris; Pierre-Olivier Bagnaninchi; Leonard J Nelson
Journal:  Sci Rep       Date:  2017-01-30       Impact factor: 4.379

4.  Dynamic Alterations of the Gut Microbial Pyrimidine and Purine Metabolism in the Development of Liver Cirrhosis.

Authors:  Yinghui Xiong; Li Wu; Li Shao; Yang Wang; Zebing Huang; Xun Huang; Chunhui Li; Anhua Wu; Zhenguo Liu; Xuegong Fan; Pengcheng Zhou
Journal:  Front Mol Biosci       Date:  2022-01-28

5.  Activation of natural killer T cells contributes to Th1 bias in the murine liver after 14 d of ethinylestradiol exposure.

Authors:  Meng-Zhi Zou; Wei-Chao Kong; Heng Cai; Meng-Tao Xing; Zi-Xun Yu; Xin Chen; Lu-Yong Zhang; Xin-Zhi Wang
Journal:  World J Gastroenterol       Date:  2022-07-14       Impact factor: 5.374

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.